Global Central Nervous System Disorders Therapeutics Market 2016-2020; New Report Launched

DrugPipeline.net has announced the addition of “Global Central Nervous System Disorders Therapeutics Market 2016-2020” research report to their website DrugPipeline.net


Bangalore, India -- (SBWIRE) -- 10/04/2016 -- CNS disorders can affect either the brain or spinal cord, or both. CNS disorders are also called as neurological and psychiatric disorders. The major causes of CNS disorders are infections, trauma, degeneration, structural defects, tumors, autoimmune disorders, and stroke. A headache, muscle weakness, memory loss, impaired mental ability, and lack of coordination are few of the symptoms of CNS disorders.

Report forecast the global central nervous system (CNS) disorders therapeutics market to grow at a CAGR of 3.38% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global central nervous system (CNS) disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington's disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.

The market is divided into the following segments based on geography:
- Americas

Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- GlaxoSmithKline
- Pfizer
- Eli Lilly
- Janssen Pharmaceuticals
- Novartis

Other prominent vendors
- AB Science
- AbbVie
- Abital Pharma
- Acorda Therapeutics
- Active Biotech
- Adamas Pharmaceuticals
- Addex Therapeutics
- Akorn
- Alcobra
- Alexza Pharmaceuticals
- Alkermes
- Amarantus
- Aprecia Pharmaceuticals
- Archer Pharmaceuticals
- Astellas
- AstraZeneca
- Aurobindo Pharma
- Auspex Pharmaceuticals
- Avanir Pharmaceuticals
- Biscayne Pharmaceuticals
- Boehringer Ingelheim
- Cerecor
- Concordia
- Convergence Pharmaceuticals
- Curemark
- CURx Pharmaceuticals
- Dainippon Sumitomo Pharma
- Dart NeuroScience
- Delpor
- Desitin Arzneimittel
- D-Pharm
- Edgemont Pharmaceuticals
- Endo International
- E-Therapeutics
- Euthymics
- Evotec
- F. Hoffmann-La Roche
- Fabre-Kramer Pharmaceuticals
- Forum Pharmaceuticals
- Gedeon Richter
- Glenmark
- Grupo Ferrer Internacional
- GW Pharmaceuticals
- H. Lundbeck
- Hisamitsu
- Impax
- Insero Health
- INSYS Therapeutics
- Intellipharmaceutics
- Intra-Cellular Therapies
- Ipsen
- Kyowa Hakko Kirin
- Ligand Pharmaceuticals
- Lupin
- MarcoPolo Pharmaceuticals
- Marinus Pharmaceuticals
- Meda AB
- Merck
- Mitsubishi Tanabe
- MSI Methylation Sciences
- Mylan
- Naurex
- Neuralstem
- Neurelis
- Neurovance
- Nobelpharma
- Noven Pharmaceuticals
- Omeros
- Opexa
- Opko Health
- Orion
- Ophelia Pharmaceutical
- Otsuka Pharmaceuticals
- Palobiofarma
- Par Pharmaceuticals
- Pierre Fabre
- Prana Biotechnology
- Raptor Pharmaceutical
- Reviva Pharmaceuticals
- SAGE Therapeutics
- Sanofi
- SciFlour
- Sedor Pharmaceuticals
- Shire
- Siena Biotech
- SK Biopharmaceuticals
- SOM Biotech
- Somerset Pharmaceuticals
- STADA Arzneimittel
- Sun Pharmaceuticalc
- Sunovion Pharmaceuticals
- Supernus Pharmaceuticals
- Suven
- Takeda Pharmaceuticals
- Teva Pharmaceuticals
- Torrent Pharmaceuticals
- Tris Pharma
- Turing Pharmaceuticals
- US WorldMeds
- Valeant Pharmaceuticals
- Zinfandel Pharmaceuticals
- Zogenix

Market driver
- New DMD approvals for AD, PD, and MS
- For a full, detailed list, view our report

Market challenge
- High failure rates of late-stage products in clinical trials
- For a full, detailed list, view our report

Market trend
- Increased uptake of new-generation drugs
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 147 pages "Global Central Nervous System Disorders Therapeutics Market 2016-2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Pipeline portfolio, Market landscape, Market segmentation by type of disease, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Appendix.

For more information Visit at: http://www.drugpipeline.net/technavio/global-central-nervous-system-disorders-therapeutics-market-2016-2020

Related Report:

Global Anesthesia Breathing Circuits Market 2016-2020; visit - http://www.drugpipeline.net/technavio/global-anesthesia-breathing-circuits-market-2016-2020

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.